Correlation Between Molecular Partners and AN2 Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and AN2 Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and AN2 Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and AN2 Therapeutics, you can compare the effects of market volatilities on Molecular Partners and AN2 Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of AN2 Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and AN2 Therapeutics.

Diversification Opportunities for Molecular Partners and AN2 Therapeutics

-0.43

Correlation Coefficient

Molecular Partners  AN2 Therapeutics

Very good diversification

The 3 months correlation between Molecular and AN2 is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and AN2 Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AN2 Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with AN2 Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AN2 Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and AN2 Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and AN2 Therapeutics

Given the investment horizon of 90 days Molecular Partners AG is expected to under-perform the AN2 Therapeutics. In addition to that, Molecular Partners is 1.52 times more volatile than AN2 Therapeutics. It trades about -0.01 of its total potential returns per unit of risk. AN2 Therapeutics is currently generating about 0.01 per unit of volatility. If you would invest  141.00  in AN2 Therapeutics on December 29, 2024 and sell it today you would lose (2.00) from holding AN2 Therapeutics or give up 1.42% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  AN2 Therapeutics

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy essential indicators, Molecular Partners is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

AN2 Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days AN2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, AN2 Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Molecular Partners and AN2 Therapeutics

The main advantage of trading using opposite Molecular Partners and AN2 Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, AN2 Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AN2 Therapeutics will offset losses from the drop in AN2 Therapeutics' long position.

The idea behind Molecular Partners AG and AN2 Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.